The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Multicentre Medical-economic Study Evaluating the Efficacy of Adding ZOlédronique Acid to STERéotaxique Radiotherapy in the Treatment of Vertebral Metastases
Official Title: Phase III Randomized, Controlled, Open, Multicentre Medical-economic Study Evaluating the Efficacy of Adding ZOlédronique Acid to STERéotaxique Radiotherapy in the Treatment of Vertebral Metastases
Study ID: NCT03951493
Brief Summary: Hypo-fractured radiotherapy in stereotactic conditions (RSHF) of bone metastases allows high doses to be delivered to the affected bone segment while sparing adjacent healthy tissues as well as possible. In addition, it not only reduces pain and prevents spinal cord compression, but also improves long-term control of metastatic disease. Zoledronic acid reduces bone complications. The economic literature shows that stereotactic radiotherapy, like zoledronic acid, are cost-effective strategies in these indications. The objective of this research project is to evaluate the efficiency of adding zoledronic acid to stereotactic radiotherapy in the treatment of vertebral metastases.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Institut BERGONIE, Bordeaux, , France
Institut de Cancérologie de Lorraine, Nancy, , France
Hôpital Privé du Confluent, Nantes, , France
Centre de Haute Energie, Nice, , France
Hopital Lyon Sud, Pierre-Bénite, , France
Centre Henri Becquerel, Rouen, , France
Stéphane SUPIOT, Saint-Herblain, , France
Name: Stéphane SUPIOT, MD
Affiliation: ICO site SAINT HERBLAIN
Role: STUDY_DIRECTOR